Search

Your search keyword '"Matricardi, P."' showing total 843 results
Start Over Author "Matricardi, P."
843 results on '"Matricardi, P."'

201. IgE recognition of the house dust mite allergen Der p 37 is associated with asthma.

Author

Huang, Huey-Jy, Resch-Marat, Yvonne, Casset, Anne, Weghofer, Margit, Zieglmayer, Petra, Zieglmayer, René, Lemell, Patrick, Horak, Friedrich, Chen, Kuan-Wei, Potapova, Ekaterina, Matricardi, Paolo M., Pauli, Gabrielle, Grote, Monika, Valenta, Rudolf, and Vrtala, Susanne

Abstract

House dust mite (HDM) allergens are major elicitors of allergic reactions worldwide. Identification, characterization, and evaluation of diagnostic utility of a new important HDM allergen was performed. A cDNA coding for a new Dermatophagoides pteronyssinus (Dp) allergen, Der p 37, was isolated from a Dp expression library with allergic patients' IgE antibodies. Recombinant Der p 37 (rDer p 37) expressed in Escherichia coli was purified, then characterized by mass spectrometry, circular dichroism, and IgE reactivity by ImmunoCAP ISAC technology with sera from 111 clinically defined HDM-allergic patients. The allergenic activity of rDer p 37 was studied by basophil activation and CD4+ T-cell responses by carboxyfluorescein diacetate succinimidyl ester dilution assays. Specific antibodies raised against rDer p 37 were used for the ultrastructural localization of Der p 37 in mites by immunogold transmission electron microscopy. Der p 37, a 26 kDa allergen with homology to chitin-binding proteins, is immunologically distinct from Der p 15, 18, and 23. It is located in the peritrophic membrane of fecal pellets. Der p 37 reacted with IgE antibodies from a third of HDM-allergic patients and induced specific basophil- and CD4+ T-cell activation. Der p 37 IgE–positive patients had significantly higher IgE levels to major HDM allergens, reacted with more HDM allergens, and had a higher risk (odds ratio = 3.1) of asthma compared to Der p 37–negative patients. Der p 37, a new Dp allergen recognized by a third of HDM-allergic patients, may serve as a surrogate marker for severe HDM sensitization and asthma. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

212. Erratum to: Long-term outcome of epilepsy in patients with Prader–Willi syndrome

Author

Verrotti, Alberto, Cusmai, Raffaella, Laino, Daniela, Carotenuto, Marco, Esposito, Maria, Falsaperla, Raffaele, Margari, Lucia, Rizzo, Renata, Savasta, Salvatore, Grosso, Salvatore, Striano, Pasquale, Belcastro, Vincenzo, Franzoni, Emilio, Curatolo, Paolo, Giordano, Lucio, Freri, Elena, Matricardi, Sara, Pruna, Dario, Toldo, Irene, Tozzi, Elisabetta, Lobefalo, Lucio, Operto, Francesca, Altobelli, Emma, Chiarelli, Francesco, and Spalice, Alberto

Published
2015
Full Text
View/download PDF

219. First reported case of an inherited PACS2pathogenic variant with variable expression

Author

Cesaroni, Elisabetta, Matricardi, Sara, Cappanera, Silvia, and Marini, Carla

Abstract

Neonatal epilepsy, cerebellar dysgenesis and facial dysmorphisms may be associated with de novo PACS2missense pathogenic variants (EIEE 66) (OMIM #618067). Here, we report a toddler boy with neonatal‐onset seizures, developmental delay with hypotonia, facial dysmorphisms and prominence of the cisterna magna, mild inferior vermian and cerebellar hypoplasia. A nextgeneration epilepsy gene panel revealed a known pathogenic PACS2missense variant, p.Glu209Lys, that was inherited from his mildly affected mother. We describe the first PACS2pathogenic variant to be inherited, expanding the clinical spectrum, associated with a mild phenotype in the mother and a more severe phenotype in her son, in keeping with previously reported descriptions.

Published
2022
Full Text
View/download PDF

220. EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis

Author

Fokkens, W., Desrosiers, M., Harvey, R., Hopkins, C., Mullol, J., Philpott, C., Alobid, I., Anselmo-Lima, W. T., Bachert, C., Baroody, F., Bernal-Sprekelsen, M., von Buchwald, C., Cervin, A., Cohen, N., Constantinidis, J., de Gabory, L., Douglas, R., Gevaert, P., Hafner, A., Hellings, P., Joos, G., Kalogjera, L., Kern, R., Knill, A., Kocks, J., Landis, B. N., Limpens, J., Lebeer, S., Lourenco, O., Matricardi, P. M., Meco, C., O Mahony, L., Reitsma, S., Ryan, D., Schlosser, R., Senior, B., Smith, T., Teeling, T., Tomazic, P. V., Toppila-Salmi, S., Wang, D. Y., Wang, D., Zhang, L., Lund, V., van Drunen, Cornelis, Ear, Nose and Throat, and AII - Inflammatory diseases

Abstract

BACKGROUND: The European Position Papers on Rhinosinusitis from 2005, 2007 and 2012 have had a measurable impact on the way this common condition with high impact on quality of life is managed around the world. EPOS2020 will be the latest iteration of the guideline, addressing new stakeholders and target users, presenting a summary of the latest literature and evolving treatment modalities, and formulating clear recommendations based on all available evidence. METHODOLOGY: Based on the AGREE II framework, this article demonstrates how the EPOS2020 steering group will address six key areas to ensure consistency in quality and presentation of information in the latest rhinosinusitis clinical practice guideline: scope and purpose; stakeholder involvement; rigour of development; clarity of presentation; recommendations and applicability; editorial independence. RESULTS: By analysing the guidance from AGREE II, we formulated a detailed development strategy for EPOS2020. We identify new stakeholders and target users and ratify the importance of patient involvement in the latest EPOS guideline. New and expanded areas of research to be addressed are highlighted. We confirm our intention to use mixed methodologies, combining evidence-based medicine with real life studies; when no evidence can be found, use Delphi rounds to achieve clear, inclusive recommendations. We also introduce new concepts for dissemination of the guideline, using Internet and social media to improve accessibility. CONCLUSION: This article is an introduction to the EPOS2020 project, and presents the key goals, core stakeholders, planned methodology and dissemination strategies for the latest version of this influential guideline.

Published
2019

221. The importance of real-life research in respiratory medicine: Manifesto of the Respiratory Effectiveness Group

Author

Roche, N. Anzueto, A. Anticevich, S.B. Kaplan, A. Miravitlles, M. Ryan, D. Soriano, J.B. Usmani, O. Papadopoulos, N.G. Canonica, G.W. Agache, I. Barnes, P. Bateman, E. Behr, J. Bjermer, L. Blakey, J. Bouros, D. Bousquet, J. Brown, K. Brusselle, G. Calderon, M. Campbell, J. Cardell, L.O. Castro-Rodriguez, J.A. Chaudhuri, N. Chavannes, N. Corte, T. Costello, R. Cottin, V. Custovic, A. Dandurand, R. Diamant, Z. Demoly, P. Ducharme, F. Feleszko, W. Fitzgerald, M. Fokkens, W. Freeman, D. Gaga, M. Geiser, T. Glaspole, I. Gouder, C. Haughney, J. Heaney, L. Hedlin, G. Hellings, P. Hoe, T.O. Israel, E. Jartti, T. Jones, M. Jones, R. Josephs, L. Kalayci, O. Keane, M. Kocks, J. Lemanske, R. Magnussen, H. Makela, M. Mazzei, M. Matricardi, P. McIvor, A. Molina, M. Morais-Almeida, M. Morell, F. Mosges, R. Mullol, J. Murray, C. Nathan, S. Navarrete, B.A. Pappi, A. Paton, J.Y. Phipatanakul, W. Price, D. Quint, J. Rhee, C.K. Ortega, P.R. Roberts, G. Sadatsafavi, M. Sastre, J. Scadding, G. Selman, M. Singh, D. Sliwinski, P. Small, I. Smith, P. Thomas, M. Tsiligianni, I. van Aalderen, W. van Bowen, J. van den Berge, M. van Ganse, E. Vetsbo, J. Vogelmeier, C. Walsh, S. Xepapadaki, V. Zar, H. the Respiratory Effectiveness Group Collaborators

Published
2019

235. Allergic bronchopulmonary aspergillosis (ABPA)

Author

Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), Crameri, R, Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), and Crameri, R

Published
2016

236. Role of microbial allergens in atopic dermatitis

Author

Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), Glatz, Martin, Bosshard, Philipp P, Crameri, Reto, Schmid-Grendelmeier, Peter, Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H J, Valenta, R, Ollert, M, Matricardi, P M ( P M ), Kleine-Tebbe, J ( J ), Hoffmann, H J ( H J ), Valenta, R ( R ), Ollert, M ( M ), Glatz, Martin, Bosshard, Philipp P, Crameri, Reto, and Schmid-Grendelmeier, Peter

Published
2016

237. Hyaluronan‐Based Nanohydrogels for Targeting Intracellular S. Aureus in Human Keratinocytes

Author

Montanari, E, Oates, A, Di Meo, C, Meade, J, Cerrone, R, Francioso, A, Devine, D, Coviello, T, Mancini, P, Mosca, L, and Matricardi, P

Abstract

Staphylococcus aureus is one of the most significant human pathogens that is frequently isolated in a wide range of superficial and systemic infections. The ability of S. aureus to invade and survive within host cells such as keratinocytes and host immune cells has been increasingly recognized as a potential factor in persistent infections and treatment failures. The incorporation of antibiotics into hyaluronan‐cholesterol nanohydrogels represents a novel paradigm in the delivery of therapeutic agents against intracellular bacteria. The work presented herein shows that NHs quickly enter human keratinocytes and accumulate into lysosomes. When used for targeting intracellular S. aureus the antimicrobial activity of loaded levofloxacin is enhanced, possibly changing the antibiotic intracellular fate from cytosol to lysosome. Indeed, gentamicin, an antibiotic that predominantly accumulates in lysosomes, shows significant and equal antibacterial activity when entrapped into NHs. These results strongly suggest that lysosomal formulations may display preferential activity toward intracellular S. aureus, opening new avenues for the use of HA‐based NHs for treatment of such skin infections.

Published
2018

238. Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy

Author

Matricardi, Sara, Casciato, Sara, Bozzetti, Silvia, Mariotto, Sara, Stabile, Andrea, Freri, Elena, Deleo, Francesco, Sartori, Stefano, Nosadini, Margherita, Pappalardo, Irene, Meletti, Stefano, Giovannini, Giada, Zucchi, Elisabetta, Di Bonaventura, Carlo, Di Gennaro, Giancarlo, Ferrari, Sergio, Zuliani, Luigi, Zoccarato, Marco, Vogrig, Alberto, Lattanzi, Simona, Michelucci, Roberto, Gambardella, Antonio, Ferlazzo, Edoardo, Fusco, Lucia, Granata, Tiziana, and Villani, Flavio

Abstract

ObjectiveTo describe the clinical and paraclinical findings, treatment options and long-term outcomes in autoimmune encephalitis (AE), with a close look to epilepsy.MethodsIn this retrospective observational cohort study, we enrolled patients with new-onset seizures in the context of AE. We compared clinical and paraclinical findings in patients with and without evidence of antibodies.ResultsOverall, 263 patients (138 females; median age 55 years, range 4–86) were followed up for a median time of 30 months (range 12–120). Antineuronal antibodies were detected in 63.50%.Antibody-positive patients had multiple seizure types (p=0.01) and prevalent involvement of temporal regions (p=0.02). A higher prevalence of episodes of SE was found in the antibody-negative group (p<0.001).Immunotherapy was prescribed in 88.60%, and effective in 61.80%. Independent predictors of favourable outcome of the AE were early immunotherapy (p<0.001) and the detection of antineuronal surface antibodies (p=0.01).Autoimmune-associated epilepsy was the long-term sequela in 43.73%, associated with cognitive and psychiatric disturbances in 81.73%. Independent predictors of developing epilepsy were difficult to treat seizures at onset (p=0.04), a high number of antiseizure medications (p<0.001), persisting interictal epileptiform discharges at follow-up (p<0.001) and poor response to immunotherapy during the acute phase (p<0.001).ConclusionsThe recognition of seizures secondary to AE represents a rare chance for aetiology-driven seizures management. Early recognition and treatment at the pathogenic level may reduce the risk of long-term irreversible sequelae. However, the severity of seizures at onset is the major risk factor for the development of chronic epilepsy.This study provides class IV evidence for management recommendations.

Published
2022
Full Text
View/download PDF

243. Fragmentação da paisagem no entorno e na Reserva de Desenvolvimento Sustentável Nascentes das Geraizeiras, Minas Gerais.

Author

Chaves Cerqueira, Marizete, Trondoli Matricardi, Eraldo Aparecido, Osni Scariot, Aldicir, and Henke de Oliveira, Carlos

Abstract

Copyright of Ciência Florestal (01039954) is the property of Ciencia Florestal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021
Full Text
View/download PDF

244. Preparation of gellan-cholesterol nanohydrogels embedding baicalin and evaluation of their wound healing activity

Author

Sapienza Università di Roma, Manconi, Maria, Manca, M.L., Caddeo, C., Cencetti, Claudia, di Meo, Chiara, Zoratto, Nicole, Nácher Alonso, Amparo, Fadda, A.M., Matricardi, P., Sapienza Università di Roma, Manconi, Maria, Manca, M.L., Caddeo, C., Cencetti, Claudia, di Meo, Chiara, Zoratto, Nicole, Nácher Alonso, Amparo, Fadda, A.M., and Matricardi, P.

Abstract

[EN] In the present work, the preparation, characterization and therapeutic potential of baicalin-loaded nanohydrogels are reported. The nanohydrogels were prepared by sonicating (S nanohydrogel) or autoclaving (A nanohydrogel) a dispersion of cholesterol-derivatized gellan in phosphate buffer. The nanohydrogel obtained by autoclave treatment showed the most promising results: smaller particles ( similar to 362 nm vs. similar to 530 nm), higher homogeneity (polydispersity index = similar to 0.24 vs. similar to 0.47), and lower viscosity than those obtained by sonication. In vitro studies demonstrated the ability of the nanohydrogels to favour the deposition of baicalin in the epidermis. A high biocompatibility was found for baicalin-loaded nanohydrogels, along with a great ability to counteract the toxic effect induced by hydrogen peroxide in cells, as the nanohydrogels re-established the normal conditions (similar to 100% viability). Further, the potential of baicalin-loaded nanohydrogels in skin wound healing was demonstrated in vivo in mice by complete skin restoration and inhibition of specific inflammatory markers (i.e., myeloperoxidase, tumor necrosis factor-alpha, and oedema.

Published
2018

245. Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs

Author

Sapienza Università di Roma, Ministerio de Educación, Cultura y Deporte, Ministerio de Economía y Competitividad, Di Meo, Chiara, Martínez Martínez, Mayte, Coviello, Tommasina, Bermejo, M., Merino Sanjuán, Virginia, Gonzalez-Alvarez, Isabel, Gonzalez-Alvarez, Marta, Matricardi, P., Sapienza Università di Roma, Ministerio de Educación, Cultura y Deporte, Ministerio de Economía y Competitividad, Di Meo, Chiara, Martínez Martínez, Mayte, Coviello, Tommasina, Bermejo, M., Merino Sanjuán, Virginia, Gonzalez-Alvarez, Isabel, Gonzalez-Alvarez, Marta, and Matricardi, P.

Abstract

[EN] Nanohydrogels based on natural polymers, such as polysaccharides, are gaining interest as vehicles for therapeutic agents, as they can modify the pharmacokinetics and pharmacodynamics of the carried drugs. In this work, hyaluronan-riboflavin nanohydrogels were tested in vivo in healthy rats highlighting their lack of toxicity, even at high doses, and their different biodistribution with respect to that of native hyaluronan. They were also exploited as carriers of a hydrophobic model drug, the anti-inflammatory piroxicam, that was physically embedded within the nanohydrogels by an autoclave treatment. The nanoformulation was tested by intravenous administration showing an improvement of the pharmacokinetic parameters of the molecule. The obtained results indicate that hyaluronan-based self-assembled nanohydrogels are suitable systems for low-soluble drug administration, by increasing the dose as well as the circulation time of poorly available therapeutic agents.

Published
2018

246. Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy.

Author

Rodríguez-Domínguez, Azahara, Berings, Margot, Rohrbach, Alexander, Huang, Huey-Jy, Curin, Mirela, Gevaert, Philippe, Matricardi, Paolo M., Valenta, Rudolf, and Vrtala, Susanne

Abstract

House dust mites (HDMs) are among the most important allergen sources containing many different allergenic molecules. Analysis of patients from a double-blind, placebo-controlled allergen-specific immunotherapy (AIT) study indicated that patients may benefit from AIT to different extents depending on their molecular sensitization profiles. Our aim was to investigate in a real-life setting whether stratification of patients with HDM allergy according to molecular analysis may enhance AIT success. Serum and nasal secretion samples from patients with HDM allergy (n = 24) (at baseline, 7, 15, 33, and 52 weeks) who had received 1 year of treatment with a well-defined subcutaneous AIT form (Alutard SQ 510) were tested for IgE and IgG reactivity to 15 microarrayed HDM allergen molecules with ImmunoCAP Immuno-solid-phase Allergen Chip technology. IgG subclass levels to allergens and peptides were determined by ELISA, and IgG blocking was assessed by basophil activation. In vitro parameters were related to reduction of symptoms determined by combined symptom medication score and visual analog scale score. Alutard SQ 510 induced protective IgG mainly against Dermatophagoides pteronyssinus (Der p) 1 and Der p 2 and to a lesser extent to Der p 23, but not to the other important allergens such as Der p 5, Der p 7, and Der p 21, showing better clinical efficacy in patients sensitized only to Der p 1 and/or Der p 2 as compared with patients having additional IgE specificities. Stratification of patients with HDM allergy according to molecular sensitization profiles and molecular monitoring of AIT-induced IgG responses may enhance the success of AIT. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

247. Social cognition and executive functions in children and adolescents with focal epilepsy.

Author

Operto, Francesca Felicia, Pastorino, Grazia Maria Giovanna, Mazza, Roberta, Di Bonaventura, Carlo, Marotta, Rosa, Pastorino, Nazareno, Matricardi, Sara, Verrotti, Alberto, Carotenuto, Marco, and Roccella, Michele

Subjects
PARTIAL epilepsy, SOCIAL perception, COGNITION, SADNESS, EMOTION recognition, THEORY of mind
Abstract

Deficits in facial emotion recognition and Theory of Mind are frequent in patients with epilepsy. Although this evidence, studies on pediatric age are few and the relation between these abilities and other cognitive domain remains to be better elucidated. The purpose of our study is to evaluate facial emotion recognition and Theory of Mind in children and adolescents with focal epilepsy, and correlate them with intelligence and executive functions. Our work is a cross-sectional observational study. Sixty-two children and adolescents aged between 7-16 years diagnosed by focal epilepsy and 32 sex/age-matched controls were recruited. All participants were administered a standardized battery tests to assess social cognition (NEPSY-II), executive functions (EpiTrack Junior) and cognitive non-verbal level (Raven Progressive Matrices). Emotion recognition mean score was significantly lower in the epilepsy group than in the controls to Student's t-test (p <0.05). Epilepsy group showed an impairment in happiness, sadness, anger and fear recognition, compared to controls (p <0.05). Theory of Mind mean score was also significantly lower in epilepsy group than controls (p <0.05). Deficits in emotion recognition seemed to be related to low age at onset of epilepsy, long duration of disease, low executive functions and low non-verbal intelligence. Deficits in Theory of Mind seemed to be related to a high seizure frequency. Our results suggest that children and adolescents with focal epilepsy had deficit in facial emotion recognition and Theory of Mind, compared to their peer. Both these difficulties seem to be related to some features of epilepsy itself. Our results also suggest that deficits in facial emotion recognition are potentially related to difficulties in executive functions and non-verbal intelligence. More studies are needed to confirm these hypotheses. • 62 children and adolescents with focal epilepsy and 32 controls were recruited. • All participants performed standardized test to assess social cognition, executive functions and cognitive non-verbal level. • Emotion recognition and Theory of Mind score was significantly lower in the epilepsy group. • Emotion recognition seemed related to age at onset and duration of epilepsy, executive functions and non-verbal intelligence. • Deficits in Theory of Mind seemed to be related to a high seizure frequency. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

248. Dinâmica espaço-temporal da extração seletiva de madeiras no estado de Mato Grosso entre 1992 e 2016.

Author

Soares Moretti, Mariana, Trondoli Matricardi, Eraldo Aparecido, Bueno da Costa, Olívia, Pedlowski, Marcos Antonio, Ferreira, Nilson Clementino, and Pereira Miguel, Eder

Abstract

Copyright of Ciência Florestal (01039954) is the property of Ciencia Florestal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results